Prevalence, awareness, management of hypertension and association with metabolic abnormalities: the Maracaibo city metabolic syndrome prevalence study

Autores/as

  • Valmore Bermúdez
  • Joselyn Rojas
  • Roberto Añez
  • Juan Salazar
  • Maria Sofia Martínez
  • María José Calvo
  • Robys González
  • Vanessa Apruzzese
  • Luis Carlos Olivar
  • Luis Miguel Bello
  • Edward Rojas
  • Alexandra Toledo
  • Adonías Lubo
  • María Corina Gómez
  • Maricarmen Chacín
  • Marjorie Villalobos
  • Miguel Aguirre
  • Manuel Velasco
  • Zafar Israili
  • José López Miranda

Palabras clave:

arterial hypertension, cardiovascular disease, prevalence, Latin America, obesity, diabetes mellitus.

Resumen

Background: The purpose of this study was to determine the prevalence and epidemiologic behavior of Hypertension (HT) in the Maracaibo Municipality, Zulia state, Venezuela. Materials and Methods: This was a cross-sectional descriptive study, where 2,230 subjects from both genders were randomly selected as part of the Maracaibo city Metabolic Syndrome Prevalence Study (MMSPS). Complete medical examination, laboratory workup and anthropometry measurements were taken. The quantitative variables were expressed as mean±SD, and comparisons were calculated using t Student test. The qualitative variables were represented as absolute and relative frequencies, and comparisons were obtained using Z test for proportions and associations with c2 test. Results: The prevalence of HT was 19.42% (20.92% in women and 17.75% in men). The prevalence of newly diagnosed individuals was 12.0%, with 8.71% in women and 16.90% in men. The overall percentage of HT was 32.02%, being 29.63% in women and 34.65% in men. Several variables were associated with HT, such as glycemic status (χ2=64.97, p<0.001), insulin resistance (c2=25.58, p<0.001) and body mass index (c2=209.952, p<0.0001). Clinical control of blood pressure was observed in 44.7% of treated and 56.6% of untreated subjects. The most frequent anti-hypertensive drugs were: Angiotensin Converting Enzyme Inhibitors with (n=105), Beta-Blockers (n=97) and Angiotensin Receptor II Blockers (n=32). Conclusion: Even though elevated numbers of AHT are observed in our population combined with low clinical control of blood pressure, there is a lower prevalence of AHT compared to other studies at regional, national or international levels. 

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Valmore Bermúdez

PhD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Joselyn Rojas

MD, Msc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Roberto Añez

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Juan Salazar

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Maria Sofia Martínez

BSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

María José Calvo

BSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Robys González

BSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Vanessa Apruzzese

BSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Luis Carlos Olivar

BSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Luis Miguel Bello

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Edward Rojas

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

 

Alexandra Toledo

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela

Adonías Lubo

MD, MgSc, PhD

Work´s Medicine Institute. School of Medicine, University of Zulia, Maracaibo – Venezuela.

María Corina Gómez

MgSc, PhD

Nutrition School. University of Zulia, Maracaibo - Venezuela

Maricarmen Chacín

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela.

Marjorie Villalobos

MD

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela.

Miguel Aguirre

MD, MSc

Endocrine and Metabolic Diseases Research Center. University of Zulia, Maracaibo – Venezuela.

Manuel Velasco

MD, PhD

Central University of Venezuela. Clinical Pharmacology Unit of José María Vargas School of Medicine, Caracas – Venezuela

Zafar Israili

MD, PhD

Department of Medicine. Emory University School of Medicine, Atlanta, GA, USA.

José López Miranda

MD, PhD

Lipid and Atherosclerosis Unit. Department of Medicine. IMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.

Descargas